tetano
Editor, Senior Moderator
Br J Haematol
. 2021 May 15.
doi: 10.1111/bjh.17506. Online ahead of print.
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain
Mar?a E Mingot-Castellano[SUP] 1 [/SUP], Patricia Alcalde-Mellado[SUP] 1 [/SUP], Cristina Pascual-Izquierdo[SUP] 2 [/SUP], Gloria Perez Rus[SUP] 2 [/SUP], Aida Calo P?rez[SUP] 3 [/SUP], Mar?a P Martinez[SUP] 4 [/SUP], Francisco J L?pez-Jaime[SUP] 5 [/SUP], Lorena Abalo Perez[SUP] 6 [/SUP], Jos? R Gonzalez-Porras[SUP] 7 [/SUP], Fernanda L?pez Fern?ndez[SUP] 8 [/SUP], Isabel S Caparr?s Miranda[SUP] 9 [/SUP], Tom?s J Gonz?lez-L?pez[SUP] 10 [/SUP], Mar?a E Moreno Beltr?n[SUP] 11 [/SUP], Rebeca Rubio Escuin[SUP] 12 [/SUP], Reyes Jimenez B?rcenas[SUP] 1 [/SUP], GEPTI (Grupo Espa?ol de Trombocitopenia Inmune)
Affiliations
Abstract
Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Espa?ol de Trombocitopenia Inmune (GEPTI)].
Keywords: COVID-19; ITP; chronic; persistent; steroids; treatment.
. 2021 May 15.
doi: 10.1111/bjh.17506. Online ahead of print.
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain
Mar?a E Mingot-Castellano[SUP] 1 [/SUP], Patricia Alcalde-Mellado[SUP] 1 [/SUP], Cristina Pascual-Izquierdo[SUP] 2 [/SUP], Gloria Perez Rus[SUP] 2 [/SUP], Aida Calo P?rez[SUP] 3 [/SUP], Mar?a P Martinez[SUP] 4 [/SUP], Francisco J L?pez-Jaime[SUP] 5 [/SUP], Lorena Abalo Perez[SUP] 6 [/SUP], Jos? R Gonzalez-Porras[SUP] 7 [/SUP], Fernanda L?pez Fern?ndez[SUP] 8 [/SUP], Isabel S Caparr?s Miranda[SUP] 9 [/SUP], Tom?s J Gonz?lez-L?pez[SUP] 10 [/SUP], Mar?a E Moreno Beltr?n[SUP] 11 [/SUP], Rebeca Rubio Escuin[SUP] 12 [/SUP], Reyes Jimenez B?rcenas[SUP] 1 [/SUP], GEPTI (Grupo Espa?ol de Trombocitopenia Inmune)
Affiliations
- PMID: 33991422
- DOI: 10.1111/bjh.17506
Abstract
Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Espa?ol de Trombocitopenia Inmune (GEPTI)].
Keywords: COVID-19; ITP; chronic; persistent; steroids; treatment.